Peptide Library / Weight & Metabolic
Tirzepatide
Also known as: The dual agonist behind Mounjaro / Zepbound
The proven dual GLP-1/GIP agonist — an approved medication class with ~20% trial weight loss, studied in research form for metabolic health.
| Typical research dose | 2.5 mg/week to start; titrate monthly (approved range 2.5–15 mg/week) |
|---|---|
| Frequency | 1× weekly |
| Route | Subcutaneous injection |
| Cycle length | Ongoing with titration; not a short cycle |
Figures reflect protocols commonly reported in the research community — not a prescription or a recommendation.
What it is
Tirzepatide is a dual GLP-1 + GIP receptor agonist — the molecule inside the approved medications Mounjaro (diabetes) and Zepbound (weight). Unlike retatrutide, it has completed trials, has full approval in its branded forms, and has years of real-world use. In research-chemical form it is the same molecule without the pharmaceutical supply chain — which is exactly why third-party testing matters so much in this category.
What the research looks at
- Weight — SURMOUNT trials: ~15–21% average body-weight loss at 72 weeks depending on dose.
- Blood sugar — superior A1c reduction vs semaglutide in head-to-head diabetes trials.
- Cardiovascular & sleep apnea — approved indications have expanded; OSA improvement data is strong.
How protocols are commonly structured
The pharmaceutical titration is the template: 2.5 mg once weekly for 4 weeks, then step up (5 → 7.5 → 10 → 12.5 → 15 mg) no faster than monthly, holding at the lowest dose that's working. Appetite suppression is the mechanism you feel; protein intake and resistance training are the standard companions to protect muscle during loss.
One standing rule for the whole GLP-1 class: anyone with a personal or family history of medullary thyroid cancer sits this category out, and anyone on diabetes medication coordinates with their prescriber first.
Reconstitution & storage
Lyophilized powder; bacteriostatic-water reconstitution (calculator). Weekly mg dosing — a 10 mg vial is a month at the starting dose, ~1 week at the top dose. Refrigerate after mixing.
Research protocols, not a prescription — talk to a physician before touching anything.